GlassScriptPhysician profile
Janet A Anciro
NPI 1578538278
$6,870.20
in general payments reported to CMS, 2019-2025
29 companies · $858 in 2025
The $858 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,542 · 2020: $578 · 2021: $1,195 · 2022: $856 · 2023: $985 · 2024: $856 · 2025: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,700.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,594.92 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,302.37 | 2019-2025 | Breztri, Farxiga, Nexium |
| Lilly USA, LLC | $638.32 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $507.93 | 2019-2025 | Jardiance, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $455.46 | 2019-2025 | Xifaxan |
| Amgen INC. | $362.67 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $350.18 | 2020-2025 | Ubrelvy, Vraylar, Qulipta |
| Exact Sciences Corporation | $325.57 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $248.45 | 2019-2024 | |
| Pfizer INC. | $225.01 | 2019-2025 | |
| Abbott Laboratories | $161.02 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Vanda Pharmaceuticals INC. | $107.78 | 2020-2022 | |
| Novocure INC. | $84.99 | 2019 | |
| Novartis Pharmaceuticals Corporation | $63.55 | 2025 | |
| Phathom Pharmaceuticals, INC. | $54.51 | 2025 | Voquezna |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $50.19 | 2019-2021 | |
| Glaxosmithkline, LLC. | $46.94 | 2019-2023 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $42.96 | 2021 | |
| Amarin Pharma, INC. | $42.44 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $35.98 | 2021-2022 | |
| Allergan, INC. | $33.51 | 2019 | |
| Alnylam Pharmaceuticals INC. | $27.77 | 2025 | Oxlumo |
| Biohaven Pharmaceutical Holding Company LTD. | $24.04 | 2022 | |
| Eisai INC. | $15.58 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.09 | 2020 | |
| Dexcom, INC. | $13.77 | 2023 | Dexcom G6 Transmitter |
| Grifols USA, LLC | $13.69 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.60 | 2019 | |
| Idorsia Pharmaceuticals US INC | $11.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Anciro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.